Skip to main content

COVID-19 treatment yields disappointing data in trial and shows it’s not easy to develop drugs

A disappointing set of data from Regeneron Pharmaceuticals Inc. and Sanofi’s mid-stage clinical trial testing Kevzara as a COVID-19 treatment underscores the traditional ups and downs of drug development that are now heightened by the global pandemic.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.